Persistent Atrial Fibrillation Clinical Trial
— PerAF APACOfficial title:
Persistent AF (Asia Pacific) Observational Study
Verified date | November 2023 |
Source | Abbott Medical Devices |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The objective of this clinical trial is to collect safety and effectiveness data for the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) in the APAC patient population for the treatment of drug refractory, symptomatic persistent atrial fibrillation when following standard electrophysiology mapping and radiofrequency (RF) ablation procedures.
Status | Terminated |
Enrollment | 82 |
Est. completion date | November 30, 2022 |
Est. primary completion date | November 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Signed informed consent 2. Documented symptomatic persistent AF, defined as continuous AF sustained >7-days but <1 year documented by: 1. Physician's note AND one of the following: 2. 24-hr Holter showing continuous AF within 90-days of the procedure OR 3. 2 ECGs (from any form of rhythm monitoring) showing continuous AF, taken at least 7-days apart 3. Refractory or intolerant to at least one Class I or III antiarrhythmic drug (AAD) as evidenced by recurrent symptomatic AF Note: Intolerant = unable, unwilling, or refusal to take AADs 4. =18 years of age 5. Able and willing to complete all pre-, post-, and follow-up testing and requirements Exclusion Criteria: 1. Continuous AF >12 months (longstanding persistent AF) 2. Previous left atrial (LA) surgical or catheter ablation for AF 3. Any cardiac procedure within 90-days prior to initial procedure (Diagnostic procedures with no intervention are not considered a surgical or percutaneous surgical procedure) 4. Coronary artery bypass graft (CABG) surgery within 6-months (180-days) prior to initial procedure 5. Valvular cardiac surgical/percutaneous procedure (i.e. ventriculotomy, valve repair or replacement and/or presence of a prosthetic or mechanical valve) 6. Any carotid stenting or endarterectomy 7. Documented or known left atrial thrombus on imaging 8. Left atrial (LA) diameter >50 mm (parasternal long axis view or by CT) 9. Left Ventricular Ejection Fraction (LVEF) <40% 10. Unable to take anticoagulation medication due to contraindication or intolerance 11. History of blood clotting or bleeding abnormalities 12. Myocardial Infarction (MI), acute coronary syndrome, Percutaneous coronary intervention (PCI) within the 3-months (90-days) prior to the initial procedure 13. Documented thromboembolic event (including TIA) within 12-months (365 days) prior to the initial procedure 14. Rheumatic heart disease 15. Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV 16. Severe mitral regurgitation (regurgitant volume = 60 mL/beat, regurgitant fraction = 50%, and/or effective regurgitant orifice area = 0.40cm2) 17. Awaiting cardiac transplantation or other cardiac surgery within 12-months (365 days) following the initial ablation procedure 18. Unstable angina at the time of the initial procedure 19. Acute illness or active systemic infection or sepsis 20. AF secondary to electrolyte imbalance, thyroid disease, acute alcohol intoxication, major surgical procedure in the preceding 3-months, or other reversible or non-cardiac cause 21. Diagnosed atrial myxoma 22. Presence of implanted implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D) 23. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms 24. Significant congenital anomaly or other anatomic or comorbid medical problem that in the opinion of the investigator would preclude enrollment in this study or compliance with the follow-up requirements or impact the scientific soundness of the clinical trial results 25. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period 26. Enrollment in an investigational study evaluating another device, biologic, or drug that may interfere with this clinical investigation at the time of the initial procedure or within 30 days prior to the initial procedure 27. Presence of any condition that precludes appropriate vascular access or manipulation of catheter 28. Life expectancy less than 12-months 29. Body mass index >40 kg/m2 30. Known sensitivity to contrast media (if needed during the procedure) that cannot be controlled with pre-medication 31. Renal failure requiring dialysis 32. Presence of other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results 33. History of atriotomy or ventriotomy 34. Implanted left atrial appendage occlusion device |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Prince of Wales Hospital | Hong Kong | |
Korea, Republic of | Sejong Hospital | Bucheon | |
Korea, Republic of | Severance Hospital, Yonsei University Health System | Seoul | |
Korea, Republic of | Asan Medical Centre | Soeul | |
Singapore | National Heart Centre Singapore | Singapore | |
Singapore | National University Hospital | Singapore | |
Taiwan | Kaohsiung Chang Gung Memorial Hospital | Kaohsiung | |
Taiwan | Taipei Veterans General Hospital | Taipei | |
Thailand | Phramongkutklao Hospital | Bangkok |
Lead Sponsor | Collaborator |
---|---|
Abbott Medical Devices |
Hong Kong, Korea, Republic of, Singapore, Taiwan, Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of Device and/or Procedure-related Serious Adverse Events | device and/or procedure-related serious adverse events are pre-defined as below with onset within 7-days of any ablation procedure that uses the TactiCath SE catheter (initial or repeat procedure performed =180 days of initial procedure)
Atrioesophageal fistula - assessed through 15 months Cardiac tamponade/perforation - assessed through 15 months Death Heart block Myocardial infarction (MI) Pericarditis - pleuritic symptoms >7 days and/or requires hospitalization >24 hrs for reasons other than observational purposes only Phrenic nerve injury resulting in diaphragmatic paralysis Pneumothorax Pulmonary edema (respiratory insufficiency) Pulmonary vein stenosis - assessed through 15 months Stroke/cerebrovascular accident Thromboembolism Transient ischemic attack Vascular access complications (including major bleeding events) |
Through 7-days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05970120 -
A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter
|
N/A | |
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT03650556 -
Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation
|
N/A | |
Recruiting |
NCT04085731 -
Driver-guided Ablation of Persistent Atrial Fibrillatiom
|
||
Withdrawn |
NCT02344394 -
Comparison of Hybrid Ablation and Pulmonary Vein Isolation Alone vs Hybrid Ablation With PVI Plus Catheter Ablation
|
N/A | |
Terminated |
NCT01683045 -
Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats
|
N/A | |
Completed |
NCT01694563 -
ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation
|
N/A | |
Active, not recruiting |
NCT03643224 -
DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation
|
N/A | |
Withdrawn |
NCT05093868 -
Electrographic Flow Mapping Validation in Patients With Persistent Atrial Fibrillation (EVAL AF)
|
N/A | |
Completed |
NCT05152966 -
Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation(PersAFOne II)
|
N/A | |
Completed |
NCT05043883 -
Automated Assessment of PVI Using a Novel EP Recording System
|
N/A | |
Completed |
NCT04022954 -
HD Mapping of Atrial Fibrillation in Asia Pacific
|
||
Active, not recruiting |
NCT06124690 -
Persistent Atrial Fibrillation Without the Evidence of Low-voltage Areas
|
N/A | |
Not yet recruiting |
NCT05454111 -
CARTO-Finder Guided Ablation Versus Multiscale Entropy Guided Ablation in Persistent Atrial Fibrillation
|
N/A | |
Completed |
NCT06260670 -
FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation
|
N/A | |
Active, not recruiting |
NCT05077670 -
Hybrid Characterization of Driver Sites During Atrial Fibrillation and Sinus Rhythm
|
||
Withdrawn |
NCT03835338 -
WATCHMAN for Concomitant Left Atrial Appendage Electrical Isolation and Occlusion to Treat Persistent Atrial Fibrillation Rhythm
|
N/A | |
Completed |
NCT02275104 -
Multimodal Image Processing Software to Guide Cardiac Ablation Therapy
|
N/A | |
Not yet recruiting |
NCT05565183 -
Combined Study of ATrial Strain and Voltage by High Density Mapping in Young Patients With Atrial Fibrillation.
|
N/A | |
Completed |
NCT02274857 -
Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures
|
N/A |